<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To identify risk factors for <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> after benign results of endometrial biopsy or dilation and curettage (D&amp;C) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Nested case-control study from Rochester Epidemiology Project data </plain></SENT>
<SENT sid="2" pm="."><plain>Among 370 Olmsted County, Minnesota, residents who received an <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> diagnosis between 1970 and 2008, we identified 90 patients (24.5%) who had previous benign endometrial biopsy or D&amp;C results (no <z:mpath ids='MPATH_483'>atypical hyperplasia</z:mpath>) </plain></SENT>
<SENT sid="3" pm="."><plain>We compared them with 172 matched control group participants who had benign endometrial biopsy or D&amp;C results without subsequent <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Using a multivariable conditional logistic regression model, we found that oral contraceptive pill (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OCP</z:e>) use was protective (odds ratio [OR] 0.18, 95% CI [CI] 0.08-0.45; P&lt;.001), and personal history of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (OR 4.44, 95% CI 1.02-19.31; P&lt;.05), endometrial <z:mpath ids='MPATH_491'>polyp</z:mpath> (OR 4.12, 95% CI 1.40-12.17; P=.01), and morbid <z:hpo ids='HP_0001513'>obesity</z:hpo> (OR 3.40, 95% CI 1.18-9.78; P&lt;.03) were independently associated with subsequent <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Compared with the presence of no risk factor, presence of one and two or more risk factors increased the risk of <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> by 8.12 (95% CI 3.08-21.44) and 17.87 (95% CI 5.57-57.39) times, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Assuming a 2.6% lifetime risk of <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e>, ORs of 8.12 and 17.87 for one and two or more of the four aforementioned risk factors confer a lifetime risk of approximately 18% and 32%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: One fourth of patients with <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> had previous benign endometrial biopsy or D&amp;C results </plain></SENT>
<SENT sid="8" pm="."><plain>Personal history of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, presence of endometrial <z:mpath ids='MPATH_491'>polyps</z:mpath>, and morbid <z:hpo ids='HP_0001513'>obesity</z:hpo> are the strongest risk factors for having <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> after a benign endometrial biopsy or D&amp;C result, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OCP</z:e> use is the strongest protective factor </plain></SENT>
<SENT sid="9" pm="."><plain>LEVEL OF EVIDENCE: II </plain></SENT>
</text></document>